The table below shows NEKTAR THERAPEUTICS's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$44.30M
-$49.05M
-$47.89M
-$51.91M
-$88.42M
-$77.08M
Capital expenditure
$18.00K
$2.00K
$157.00K
$433.00K
$4.20M
$2.88M
Investing cash flow
-$350.79M
$43.69M
$19.26M
$40.60M
$130.28M
$10.46M
Dividends paid
-
-
-
-
NKTR operating cash flow (10-K history)
NEKTAR THERAPEUTICS reported operating cash flow of -$208.51M for fiscal year 2025. That is down 18.7% from -$175.71M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$117.02M (FY 2016) to -$208.51M. Figures come from the company's audited annual reports as filed with the SEC.
